BAC
Bank of America Corporation
BAC's fundamentals are strong: its operating margin rose 5 points to 35% and revenue grew 15%. At 12x earnings, it's trading in line with its usual 13x. Analysts expect earnings growth.
MRX
Marex Group plc Ordinary Shares
There isn't enough reported data to score MRX yet.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
MRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| N/A | |
| N/A |
There isn't enough reported data to rate MRX's fundamentals.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
MRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | N/A | N/A |
| Fair | 14x | N/A | N/A |
| Expensive | 17x | N/A | N/A |
| Current | 18x | $71.68 | — |
Historical ranges are pointers, not guarantees.
MRX's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
MRX Forward outlook
There aren't enough analyst estimates for MRX to show an outlook.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
MRX Earnings Per Share
MRX and BAC do not have enough comparable growth data to identify a winner.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
MRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2B | +306% |
| Q4 2025 | $3.1B | +45% |
| Q2 2025 | $500.1M | -32% |
| Q4 2024 | $2.2B | +199% |
| Q2 2024 | $740M | -36% |
| Q4 2023 | $720.7M | +109% |
| Q2 2023 | $1.2B | +75% |
| Q4 2022 | $345.3M | -16% |
MRX has the edge over BAC in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 59% | +6.1 points |
| Q4 2025 | 34% | +50 points |
| Q2 2025 | 20% | +19 points |
| Q4 2024 | 20% | +2.2 points |
| Q2 2024 | 53% | +47 points |
| Q4 2023 | -16% | -25 points |
| Q2 2023 | 0.8% | -7.5 points |
| Q4 2022 | 18% | +13 points |
MRX has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
MRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $692M | -25% |
| Q4 2025 | -$264.5M | -138% |
| Q2 2025 | $918.9M | +107% |
| Q4 2024 | $704.6M | +95% |
| Q2 2024 | $443.3M | +23% |
| Q4 2023 | $361.5M | +234% |
| Q2 2023 | $361.5M | +234% |
| Q4 2022 | $108.1M | -53% |
MRX's free cash flow was $2.1B over the past year, up 61% from the year before. Free cash flow isn't a meaningful measure for financial services companies like MRX.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over MRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
MRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -487K shares |
| 1 year | +4.7% | +3.4M shares |
| 3 years | +25% | +15M shares |
MRX has 76M diluted shares, up 4.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $125.6M |
| Q4 2025 | $200,000 |
| Q2 2025 | — |
| Q4 2024 | — |
| Q2 2024 | $19.8M |
| Q4 2023 | $1.6M |
| Q2 2023 | $1.6M |
| Q4 2022 | $4M |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
MRX Net Leverage
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
MRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 40.9 | Neutral |
MRX's weekly RSI is 59 (neutral) and its Stochastic is 41 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over MRX on valuation relative to its sector.
MRX PE vs Financial Services Sector
| Metric | MRX | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 13x | 42% above |
| PE % | 93 | 29 | 64 pts above |
MRX is trading at 18x earnings, a 42% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
MRX has stronger trend alignment. BAC is above 1 of 5 weekly averages versus MRX above 4 of 4.
MRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $69.8 | 2.6% above |
| 20 week MA | $69.1 | 3.8% above |
| 50 week MA | $55.3 | 30% above |
| 100 week MA | $45.7 | 57% above |
MRX is in an uptrend: it's above all four of its weekly moving averages, and 57% above its 100-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
MRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $19.0 | $31.9 | +68% |
| 2025 | $31.9 | $39.6 | +24% |
| 2026 YTD | $39.6 | $71.7 | +81% |
MRX has the edge over BAC on returns for 2026, with the stronger performance.